Patients with beta (β)-thalassemia (β-TM: thalassemia major, β-TI: thalassemia intermedia) have a variety of complications that may affect all organs, including the eye. Ocular abnormalities include retinal pigment epithelium degeneration, angioid streaks, venous tortuosity, night blindness, visual field defects, decreased visual acuity, color vision abnormalities, and acute visual loss. Patients with β-TM are transfusion dependent and require iron chelation therapy (ICT) in order to survive. Retinal degeneration may result from either retinal iron accumulation from transfusion-induced iron overload or retinal toxicity induced by ICT. Some who were never treated with ICT exhibited retinopathy, and others receiving ICT had chelator-induced retinopathy. We will focus on retinal abnormalities present in individuals with β-TM viewed in light of new findings on the mechanisms and manifestations of retinal iron toxicity.
Introduction
Normal hemoglobin consists of tetramers composed of two homo-dimers. Adult (HbA) and fetal (HbF) hemoglobins consist of two alpha-chains combined with beta (HbA, α 2 β 2 ), delta (HbA 2 , α 2 δ 2 ), or gamma chains (HbF, α 2 γ 2 ). Hemoglobinopathies are disorders caused by mutations in specific globin genes such as α or β, leading to ineffective erythropoiesis. 17 ; 95 β-thalassemia is an autosomal recessive disorder caused by defective β globin production. In its severe form, affected individuals require regular blood transfusions to survive. Disease severity is determined by the degree of β-globin chain production. Patients with thalassemia major have markedly diminished β-globin chain production and have the most severe phenotype, requiring regular blood transfusions in order to survive. Patients with thalassemia intermedia have more β-globin chain production than those with thalassemia major, reducing the severity of the disease, but sometimes need blood transfusions. The result of this defective β-globin chain production is an imbalanced globin chain production with excess α-chains. The abnormal red blood cells suffer premature destruction from oxidative damage of the cell membrane in the bone marrow. 17 ; 65 gene expression and protein levels in a β-thalassemia mouse model. 12 ; 66 There was a 25% reduction in the levels of Abcc6 protein in the β-thalassemia mouse model at age 10 months. 66 Thus, β-thalassemic patients could have diminished ABCC6 gene expression leading to the PXE-like syndrome. 12 ; 63 PXE is characterized by calcium mineralization of elastic fibers (elastin). 33 Calcium and other minerals are deposited in elastin in the blood vessels, skin, and Bruch's membrane under the retinal pigment epithelial cells. 33 ; 37 Various studies from the early 1990s demonstrated similar ocular manifestations in β-thalassemia and PXE. 1 ; 6 ; 12 ; 15 ; 51 Aessopos and colleagues established the terms "PXE-like-lesion" and "PXE-like syndrome" to help differentiate PXE from acquired PXE-like syndrome findings. 5 PXE-like syndrome refers to the following retinal abnormalities: angioid streaks, peau d'orange, and optic disc drusen development. Retinal venous tortuosity (RVT) is considered the primary non-PXE like retinal abnormality found in β-thalassemia. 12 Some β-thalassemia-associated retinal pathologies cited in the literature include retinal pigment epithelium (RPE) degeneration, RPE mottling, angioid streaks, retinal vessel tortuosity, retinal hemorrhages, retinal edema, pseudo-papillitis, and macular scarring. 9 ; 36 ; 76 ; 84 ; 86 We performed a meta-analysis on five cross-sectional studies by identifying common ocular findings among the papers and calculating prevalence values (Table 1) .
We identified retinal abnormalities in β-TM patients associated with transfusional iron overload in the literature. These patients had not received iron chelation therapy (ICT). RPE mottling, retinal venous tortuosity, and angioid streaks occurred in this subset of individuals ( Table 2) . As a point of clarification, RPE degeneration was described as early hyperfluorescence on fluorescein angiography. 36 Taher and colleagues defined RPE degeneration as "salt and pepper" appearance in the macula or pigmentation in the peripheral retina. 86 RPE mottling was also described as hyper-and hypo-autofluorescence shown on fundus autofluorescence (FAF) imaging. 80 ; 89 
Pseudoxanthoma (PXE)-like retinal abnormalities
2.2.1. Peau d'orange-Peau d'orange refers to small confluent dark yellowish lesions at the level of the retinal pigment epithelium. 37 This finding often precedes angioid streaks. Initially, calcification of the Bruch's membrane occurs at the posterior pole and spreads centrifugally. This is associated with the peau d'orange appearance. Barteselli and colleagues found peau d'orange was the most frequent finding in β-thalassemic patients. 12 Angioid streaks are usually an asymptomatic finding on retinal examination. Angioid streaks become problematic when the lesion extends towards the foveola or develops complications such as macular choroidal neovascularization (CNV) and traumatic Bruch's membrane rupture. 6 84 Chronically anemic patients demonstrated an inverse relationship between hematocrit and RVT. 7 RVT increases with age in β-thalassemics when compared to age-matched non-thalassemics. The mild and chronic anemia that occurs in between transfusions results in tissue hypoxia leading to RVT. 56 Additionally, splenectomy correlates with increased vascular tortuosity, potentially because of increased thrombotic risk post-splenectomy. 12 
Conclusions
β-thalassemia and PXE share similar ocular fundus changes. This suggests a similar PXElike elastin calcification may occur in β-thalassemia. Importantly, PXE and β-thalassemia share the following retinal findings: peau d'orange, angioid streaks, and ONH drusen. Comet lesions, common to PXE, have not been found with β-thalassemia. Patients with β-TI have a higher risk of developing PXE-like retinal abnormalities than β-TM patients.
Iron and the retina

Overview
Iron toxicity from multiple blood transfusions may contribute to β-thalassemia retinopathy. In general, iron is an important component of many metabolic processes, but appropriate regulation is necessary in order to prevent toxicity. 81 ; 97 In the retina, iron is needed in the visual phototransduction cascade for isomerohydrolase activity carried out by the RPE65 protein in the retinal pigment epithelium. 68 Mouse models reveal that systemic iron overload through intraperitoneal injections can lead to increased iron levels in the RPE. 100 Iron in the retina becomes problematic when ferrous iron (Fe 2+ ), which can generate hydroxyl radicals from hydrogen peroxide in the Fenton reaction, causes oxidative damage to the retina and RPE. 43 ; 70 Therefore, there are regulatory mechanisms for the import and export of iron from the eye. Iron in the systemic circulation is deterred from entering the retina by the intercellular tight junctions of the neuroretinal vasculature and RPE. 81 Moreover the cells comprising these barriers regulate its import. Once in the retina ferric iron (Fe 3+ ) can bind to transferrin, an iron-binding protein that is abundant in the vitreous and aqueous humors. 45 ; 82 Iron export from retinal cells is facilitated by multicopper ferroxidases, such as ceruloplasmin (Cp) and its homolog hephaestin (Heph). 96 Their function in iron export has been highlighted in mice with combined deficiency of Cp and Heph leading to age-dependent iron accumulation in the retina and RPE resulting in degeneration. 30 ; 49 The RPE becomes hypertrophic, autofluorescent, and dysplastic. Ferroportin, the only known mammalian iron exporter, works in cooperation with Cp and Heph. Moreover, ferroportin is also expressed in the mouse retina and RPE. 48 Retinal pathologies in thalassemic patients notably involve the retinal pigment epithelium (RPE). 9 ; 36 ; 84 ; 86 The RPE has been hypothesized as the site of increased iron deposition in β-TM patients. 84 A post-mortem β-TM eye exhibited iron deposits with Perls stain in the non-pigmented ciliary epithelium, ciliary muscle, choroidal stromal cells, sclera, peripheral retina, and occasionally in the photoreceptor layer and RPE. 74 Increased RPE iron deposition and subsequent iron overload has been correlated with RPE damage and degeneration. 28 
RPE hypertrophy
Ceruloplasmin/hephaestin double knockout mice accumulated iron in the RPE that led to RPE hyperplasia and hypertrophy in mice that survived until 12 to 13 months. 43 The RPE stress response is characterized by RPE de-differentiation and hypertrophy. A similar stress response was observed in RPE cells of mice with conditional knockout of the mitochondrial RNA polymerase, which had activation of the AKT/ mammalian target of rapamycin (AKT/ mTOR) pathway. 99 The mTOR pathway allows the RPE cell to prolong its survival at the cost of epithelial characteristics leading to disrupted interactions with the surrounding photoreceptor cells. In the postmortem eye from a patient with β-TM, the RPE cells were enlarged and projected into the subretinal space. Additionally, transmission electron microscopy demonstrated RPE cell structural variations: swollen mitochondria, thickened Bruch's membrane under the degenerated or depigmented RPE cells, and loss of basal plasma membrane infolding. It is important to note that β-TM, transfusional iron overload, DFO toxicity, or both could have caused this pathology. 74 
Iron chelation therapy
Overview of chelation therapy
Iron overload is unavoidable in patients who undergo life-long hypertransfusion therapy. Each unit of transfused blood introduces 200 to 250 mg of elemental iron into the body. Since iron cannot be actively excreted and is poorly used in individuals with ineffective erythropoiesis secondary to β-TM, excess iron is deposited in the viscera (i.e. liver, heart, pancreas, and possibly, eye). 17 Patients who receive transfusions have an average intake of 8 to 16 mg of elemental iron per day, as opposed to the normal intake of 1-to 2-mg of dietary iron per day . Furthermore, accelerated oral iron uptake in thalassemic patients contributes to the total iron overload. Iron chelation therapy (ICT) is necessary to reduce the iron burden. 65 ICT is initiated before age 6. Once initiated, ICT must be rigorously followed and frequently monitored in order to be effective and prevent complications such as heart failure and endocrine dysfunction (e.g. pancreatic failure, infertility). Furthermore, several studies have shown in mouse models of retinal iron overload that ICT may slow progression of retinal damage. 67 Table 3 summarizes the advantages and disadvantages of the current clinically available iron chelators.
Iron chelation (IV and subcutaneous): Deferrioxamine (DFO)
Deferrioxamine mesylate (DFO), an iron-chelating drug, is used to treat transfusion-related hemochromatosis. DFO was the first ICT that effectively prolonged the survival of β-thalassemic patients from the second decade of life to a normal lifespan. The side effects of DFO are numerous and include bone dysplasia, auditory toxicity, and retinal toxicity.
DFO ocular toxicity
DFO-induced ocular toxicity includes symptoms of night blindness, impaired color vision, impaired visual field, reduced visual acuity, and RPE changes (i.e. macular or peripheral pigmentary degeneration). 11 91 The standard dosage of DFO in patients ranges from 25-50 mg/kg/d. 50mg/kg/d was noted to be the upper limit before ocular and ototoxicity presents. 22 The first study documenting ocular toxicity indicated 100 mg/kg/d DFO as a dose that would cause toxicity. 25 DFO retinopathy has been assigned specific criteria. 91 We summarize 29 articles related to DFO retinopathy in Table 4 . Intravenous DFO seems to present a greater risk of retinal toxicity compared to subcutaneous and intramuscular. 11 In studies from 1983 to 2008, investigators performed retinal examinations utilizing dilated fundus examinations (DFE), fluorescein angiogram (FA), electro-retinography (ERG), electro-oculogram (EOG), and visual evoked potentials (VEP). Studies after 2008 utilized spectral domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) ( Table 4) . Several papers discussed the phenomenon of DFO retinopathy reversibility. 11 ; 13 ; 18 ; 25 ; 27 In some cases, the cessation of DFO led to a partial or complete reversal of visual symptoms and retinal findings. DFO related ocular toxicity indicates the need for ophthalmic examinations in individuals on DFO therapy. 11 ; 50 The RPE undergoes pathologic change in DFO retinopathy. 89 ; 91 ; 92 ; 98 Abnormal fluorescence on FA or FAF provide a gauge of retinal and RPE damage. 50 ; 92 Moreover, Viola and colleagues indicated that FAF imaging is a more sensitive modality than ophthalmoscopy for detecting RPE abnormalities. 92 Recent studies have indicated that several stages of maculopathy exist and may influence visual outcomes if early intervention is initiated. Please refer to section 5 for a more detailed discussion on disease management and recommendations.
Iron chelation (Oral): Deferiprone and Deferasirox
Deferiprone (DFP) and deferasirox are two oral iron chelators that provide an alternative to deferrioxamine ICT (Table 3) . DFP has been shown in various murine studies to provide effective retinal iron chelation. This is because of DFP's ability to cross the blood-retinalbarrier and chelate intracellular iron with no evidence of retinal toxicity. 23 ; 34 ; 81 ; 83 Approximately 1% of patients have severe side effects, specifically reversible agranulocytosis and neutropenia. Deferasirox provides effective systemic iron chelation, but there is no evidence of retinal penetration.
Deferiprone: a potential retinal protective iron chelator
Deferiprone (DFP) can be administered orally with fewer systemic side effects than DFO, most of which can be prevented or reversed by careful monitoring. 34 ; 81 Ceruloplasmin (Cp) and its homolog Heph (hephaestin) are two ferroxidases that regulate iron. When Cp and Heph are deficient, iron overload occurs within the retina. 81 Oral DFP administered to iron overloaded Cp/Heph deficient mice effectively decreased retinal iron and oxidative stress levels. 46 Moreover, DFP demonstrated significant protection of the saturated rod and cone-b waves in ERG studies in mice treated with sodium iodate (NaIO3) alone and cotreated with NaIO3 and DFP. 44 Furthermore, oral DFP was shown to protect the retina against NaIO3 induced oxidative stress, as indicated by reduced expression of the stressrelated gene heme-oxygenase-1 and the complement gene C3. 44 Mice deficient in the iron regulatory hormone hepcidin (Hepc) develop systemic and retinal iron overload over time. DFP treatment of Hepc deficient mice protected against RPE depigmentation and autofluorescence, preserved RPE and photoreceptor morphology, and preserved ERG rod aand b-and cone b-wave amplitudes. 83 Finally, in non-iron-overloaded pathologies such as light damage-induced photoreceptor death, DFP proved to be protective. 82 Two studies documented RPE degeneration associated with deferiprone use; 86 ; 87 however, it was not possible to determine whether the degeneration was caused by iron toxicity, toxicity from prior DFO treatment, or any potential deferiprone toxicity.
Disease management
The management of β-TM requires chronic hypertransfusion therapy and iron chelation in order to permit prolonged survival. 17 ; 65 As mentioned earlier, iron chelation therapy is necessary to counteract the iron overload that results from the hypertransfusion regiment. The iron overload caused by the transfusion therapy and the iron chelator-induced toxicity both increase the need for thalassemic patients to undergo regular ophthalmic evaluations. 9 ; 31 ; 56 ; 57
Retinal Abnormalities
Adverse retinal effects may occur as a result of the iron chelators or the disease itself and include the following: retinal pigment epithelium (RPE) degeneration, RPE mottling, retinal venous tortuosity, and vitreoretinal hemorrhages. Thalassemic patients may present with decreased visual acuity, color vision anomalies, night blindness, cataracts, visual field defects, and optic neuropathy. 9 Spectral domain-optical coherence tomography (SD-OCT), a non-invasive technique that uses low coherence light reflected by the retinal tissue, 8 can measure retinal nerve fiber layer (RNFL) thickness and provide a basic, noninvasive histological view of the retina. 8 ; 31 Recent studies have evaluated β-TM children RNFL thickness values with SD-OCT, and determined that β-thalassemics have a thinner RNFL in all quadrants when compared to children with iron deficiency anemia and normal non-anemic children. 8 Microperimetry records the patient's sensitivity to a visual stimulus and correlates that to the structure of the retina at the location of the stimulus. 90 Gelman et al demonstrated an overall decreased macular sensitivity and attenuation in the inferotemporal macula. 39 ; 40 The use of this advanced visual field technology is not widely used in the assessment of β-thalassemic patients with DFO induced retinopathy. When more evidence is available, microperimetry might play an important role in the ophthalmic evaluation of these individuals.
Iron chelator induced retinopathy: staging and assessment
DFO retinopathy is classically described as a "bull's eye maculopathy" on retinal examination. 40 ; 74 The advent of more sophisticated and refined ophthalmic technologies has made it possible to detect subtle retinal changes primarily attributed to DFO toxicity. The retinal changes occur at the RPE-Bruch's membrane-photoreceptor complex. 91 ; 92 We will focus on recent studies and summarize their recommendations.
The confocal scanning laser ophthalmoscope (cSLO) allows practitioners to evaluate RPE lipofuscin accumulation. Lipofuscin is a non-degradable end product of photoreceptor outer segment breakdown and the bisretinoid A2E. This end product has autofluorescent properties and builds up in the RPE. The SLO takes advantage of this lipofuscin deposition by detecting changes in fundus autofluorescence (FAF). FAF has been established as a superior non-invasive prognostic tool that can detect early changes of retinal toxicity. 26 ; 54 ; 55 ; 60 ; 75 ; 85 ; 93 Viola et al established four phenotypic patterns of abnormal FAF: minimal change, focal, patchy, and speckled. 92 Near-infrared reflectance (NIR) is another imaging modality (as part of the SLO) used to evaluate retinal structure 32 The NIRautofluorescence signal is thought to represent melanin. 59 Recently, the same team elucidated the benefit of a multimodal imaging assessment (FAF, NIR, SD-OCT) in β-thalassemic patients who were diagnosed with DFO-induced retinopathy. By modifying a classification system for pattern dystrophy, Viola et al, created the following categories: butterfly shaped-like, fundus flavimaculatus-like, fundus pulverulentus-like, vitelliformlike dystrophy, and minimal change. 91 The results of these papers and others are summarized in Table 5 .
Assessment of retinal function-
The ERG is a functional evaluation of the retina. Synchronized activation of retinal cells leads to electrical currents released in the same direction, resulting in an electrical potential. The full field or global ERG is a mass electrical response of the retina to a light stimulus. In humans, corneal contact lens electrodes are employed to aid in recording the electrical potential that is emitted after a photic stimulation by the ERG light-emitting diodes (LEDs). 77 The photic stimulus elicits a biphasic waveform composed of an a-and b-wave. The a-wave, the first large negative deflection, represents the photoreceptor potential from the outer retina. The b-wave, the first positive deflection, represents the ON bipolar cells and the Müller cell activation from the middle layer of the retina. Oscillatory potentials (OPs) are found on the ascending limb of the b-wave, and most likely represent a modulating effect of amacrine cells on the b-wave. Additionally, the c-wave originates in the RPE, and the d-wave indicates activity of the OFF bipolar cells. Furthermore, the electro-oculogram (EOG) is an eye-movement dependent voltage recorded between two electrodes placed at either corner (canthus) of an eye. The EOG measures the transepithelial potential (TEP) of the RPE. Recently, multifocal ERG (mfERG) has been developed to provide a detailed evaluation of the central retinal health. 77 Several studies have employed ERG in their testing arsenal when evaluating DFO-induced retinopathy in β-thalassemic patients. Likely, retinal damage occurs through iron overload induced free radical damage or by way of DFO specific cellular toxicity. 10 ; 16 Jiang et al, demonstrated abnormal scotopic sensitivity threshholds, suggestive of rod dysfunction in patients who had received more than nine years of transfusion therapy without iron chelation. They concluded that iron might have damaged rods when the patients became iron overloaded. 57 Moreover, they concluded that iron chelation therapy protected against iron induced retinal damage. 10 80 From the studies presented, ERG and EOG measures can provide additional information that can support DFO-induced retinopathy in β-TM patients. At the moment, it is unclear whether ERG and EOG provide early identification when compared to FAF, NIR, and SD-OCT.
Future directions
RPE Hemoglobin synthesis and secretion
Tezel et al demonstrated that RPE cells are capable of producing and secreting hemoglobin. 88 The proposed necessity for RPE hemoglobin production is to maintain a steady flow of oxygen to the neurosensory retina. 58 ; 88 Interestingly, Tezel et al revealed hemoglobin is the most abundant protein in the normal human RPE. Furthermore, the RPE can be induced by monomethylfumarate to produce HbF in vivo and in vitro. 73 There may be ineffective RPE hemoglobin expression in β-TM and β-TI patients. As mentioned, β-TM is caused by a quantitative loss of the beta gene and thus a decreased HbA tetramer production (α 2 β 2 ). This ineffective RPE hemoglobin production could lead to hypoxia induced retinal damage that contributes to the various thalassemia related retinal pathologies (Table 1) .
Hepcidin regulation
β-thalassemics have low levels of hepcidin, an iron regulatory hormone. This permits more iron absorption from food. Recent studies in murine models have evaluated the role of the Bhoiwala and Dunaief Page 9
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serine protease TMPRSS6, which decreases hepcidin production. 78 ; 79 Another demonstrated that a combination of deferiprone (oral iron chelation therapy) and siRNA suppression of Tmprss6 provides a promising treatment for anemia and secondary iron loading seen in β-TI (transfusion independent thalassemia). 35 Furthermore, this therapy may also be beneficial for β-TM (transfusion dependent thalassemia). Between blood transfusions, β-TM patients will have reactivated their endogenous erythropoiesis, leading to decreased hepcidin production causing increased intestinal iron absorption. 20 ; 35 Therefore, transfusion induced hemochromatosis can be controlled by using iron chelation therapy to reduce the stored iron from the body and potentially using a hepcidin analog (PR73, minihepcidin) to reduce the uptake of dietary iron. 20 
Conclusion
Practitioners need to be vigilant to detect retinopathy caused by thalassemia itself, transfusional iron overload, or iron chelators. The availability of relatively new oral iron chelators now permits treatment that may minimize retinal complications. If retinal complications occur, close follow-up using various imaging modalities may help to lessen the retinal damage.
Method of Literature Search
In November, 2014, a comprehensive electronic search using the PubMed and Medline databases using the following single and combinations of key words (DFO retinopathy, ophthalmology, retinopathy, iron chelator induced retinopathy, hepcidin, beta-thalassemia intermedia, beta-thalassemia major, iron overload, retina, deferiprone, deferrioxamine, angioid streaks, transfusional iron overload, and pseudoxanthoma elasticum-like) was used to collect pertinent publication in this field. Furthermore, references identified within these articles were also included. We collected and retrieved a total of 153 publications. From the 153 publications we included a total of 115 references. References were included if they discussed retinal abnormalities in beta-thalassemic major individuals. 101 references were cited in the main manuscript text and 14 unique references were cited in the "tables" section (tables section includes a total of 35 citations, 14 unique and 21 overlapping with manuscript text). Moreover, articles discussing deferrioxamine induced retinal toxicity were included even without concurrent incorporation of beta-thalassemia major patients. We excluded references that did not demonstrate retinopathy that was caused by either transfusional iron overload or iron-chelator therapy toxicity. Discussions regarding future directions included references related to both beta-thalassemia major and intermedia pathologies when the article demonstrated content that was translational to both severities of disease. Two book chapters were included 1) because of analysis of iron chelators and discussion of iron induced retinal damage and 2) because of discussion of electrophysiology. Meta-analysis for the prevalence of ocular abnormalities in β-Thalassemia Case-series; non-consecutive 
